Abstract: The present invention provides screening procedures for identifying inhibitors of components of regulatory networks by a positive phenotype and modified yeast cell lines suitable for said screening. The screening procedures are especially suited to screen for substances that re-sensitize resistant pathogenic microorganisms or tumor cells by suspending the expression of resistance-relevant genes. The invention further provides methods for constructing said cell lines and their use in screening systems.
Type:
Grant
Filed:
November 25, 2005
Date of Patent:
September 1, 2015
Assignees:
The South Bohemian University
Inventors:
Milan Höfer, Jost Ludwig, Petra Schwanewilm, Julius Subik
Abstract: Disclosed herein are point mutations in the LMNA gene that cause HGPS. These mutations activate a cryptic splice site within the LMNA gene, which leads to deletion of part of exon 11 and generation of a mutant Lamin A protein product that is 50 amino acids shorter than the normal protein. In addition to the novel Lamin A variant protein and nucleic acids encoding this variant, methods of using these molecules in detecting biological conditions associated with a LMNA mutation in a subject (e.g., HGPS, arteriosclerosis, and other age-related diseases), methods of treating such conditions, methods of selecting treatments, methods of screening for compounds that influence Lamin A activity, and methods of influencing the expression of LMNA or LMNA variants are also described.
Type:
Grant
Filed:
September 12, 2013
Date of Patent:
August 25, 2015
Assignees:
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, Research Foundation for Mental Hygiene, Inc., The Progeria Research Foundation, Inc.
Inventors:
B. Maria H. Eriksson, Francis S. Collins, Leslie B. Gordon, William Ted Brown
Abstract: The invention relates to orthogonal pairs of tRNAs and aminoacyl-tRNA synthetase that can incorporate unnatural amino acid into proteins produced in eubacterial host cells such as E. coli, or in a eukaryotic host such as a yeast cell. The invention provides, for example but not limited to, novel orthogonal synthetases, methods for identifying and making the novel synthetases, methods for producing proteins containing unnatural amino acids, and translation systems.
Type:
Grant
Filed:
June 8, 2012
Date of Patent:
August 11, 2015
Assignee:
The Scripps Research Institute
Inventors:
Peter G. Schultz, Lital Alfonta, Johnathan R. Chittuluru, Alexander Deiters, Dan Groff, Daniel Summerer, Meng-Lin Tsao, Jiangyun Wang, Ning Wu, Jianming Xie, Huaqiang Zeng, Mohammad Seyedsayamdost, James Turner
Abstract: The present invention provides oligonucleotide constructs, sets of such oligonucleotide constructs, and methods of using such oligonucleotide constructs to provide validated sequences or sets of validated sequences corresponding to desired ROIs. Such validated ROIs and constructs containing these have a wide variety of uses, including in synthetic biology, quantitative nucleic acid analysis, polymorphism and/or mutation screening, and the like.
Abstract: The invention relates to the fields of screening assays, compounds, and methods for altering gene expression and protein levels. In particular, the invention includes assays to screen for agents capable of modulating gene expression in a UTR-dependent manner and agents capable of modulating gene expression.
Type:
Grant
Filed:
July 21, 2004
Date of Patent:
June 30, 2015
Assignee:
PTC Therapeutics, Inc.
Inventors:
Liangxian Cao, Anuradha Mehta, Nikolai A. Naryshkin, Matthew C. Pellegrini, Charles M. Romfo, Panayiota Trifillis, Christopher R. Trotta
Abstract: The “instant evolution” system was initially developed in E. coli, primarily because of the ease with which this organism can be genetically manipulated. Because many of the functionally important regions of rRNA are conserved among bacteria, drug leads developed against conserved targets in the E. coli system may produce broad-spectrum anti-infectives. In order the develop a system to product narrow-spectrum anti-infectives, herein we disclose methods for identifying functional mutant P. aeruginosa ribosomes suitable as drug targets and for identifying drug candidates that do not bind to the human 16S rRNA.
Abstract: The present invention embraces a recombinant prokaryotic host cell containing nucleic acids encoding an eukaryotic UDP-GaINAc:UDP-GaINAc polypeptide transferase and expressing an UDP-GIcNAc C-4 epimerase and methods for using the same to produce an O-glycosylated protein.
Type:
Grant
Filed:
December 14, 2010
Date of Patent:
June 9, 2015
Assignee:
Trustees of Dartmouth College
Inventors:
Tillman U. Gerngross, Grant E. Henderson, Errik Anderson
Abstract: The present invention relates to the production of covalently closed circular (ccc) recombinant DNA molecules such as plasmids, cosmids, bacterial artificial chromosomes (BACs), bacteriophages, viral vectors and hybrids thereof, and more particularly to vector modifications that improve production yield of said DNA molecules in fermentation culture.
Abstract: The present invention relates to production of polyketides and other natural products and to libraries of compounds and individual novel compounds. One important area is the isolation and potential use of novel FKBP-ligand analogs and host cells that produce these compounds. The invention is particularly concerned with methods for the efficient transformation of strains that produce FKBP analogs and recombinant cells in which cloned genes or gene cassettes are expressed to generate novel compounds such as polyketide (especially rapamycin) FKBP-ligand analogs, and to processes for their preparation, and to means employed therein (e.g. nucleic acids, vectors, gene cassettes and genetically modified strains).
Type:
Grant
Filed:
March 11, 2011
Date of Patent:
May 26, 2015
Assignee:
Buck Institute for Research on Aging
Inventors:
Matthew Alan Gregory, Sabine Gaisser, Hrvoje Petkovic, Steven Moss
Abstract: The present invention relates to systems and methods for measuring the rate of translation of a target protein in cells, which are based on the detection of translation of one or more predetermined codon pairs during synthesis of the target protein. The detection is provided by a FRET signal emitted from labeled tRNA molecules which are juxtaposed during synthesis of the protein.
Type:
Grant
Filed:
September 21, 2010
Date of Patent:
May 19, 2015
Assignee:
ANIMA CELL METROLOGY INC.
Inventors:
Zeev Smilansky, Barry S. Cooperman, Yale E. Goodman
Abstract: The present invention provides a method for obtaining site-specific recombination in a eukaryotic cell, the method comprising providing a eukaryotic cell that comprises a first recombination attachment site and a second recombination attachment site; contacting the first and second recombination attachment sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination attachment sites, wherein the recombinase polypeptide can mediate recombination between the first and second recombination attachment sites, the first recombination attachment site is a phage genomic recombination attachment site (attP) or a bacterial genomic recombination attachment site (attB), the second recombination site is attB or attP, and the recombinase is selected from the group consisting of a Listeria monocytogenes phage recombinase, a Streptococcus pyogenes phage recombinase, a Bacillus subtilis phage recombinase, a Mycobacterium tuberculosis phage recombinase and a Mycobacterium smegmatis pha
Abstract: Linear vectors derived from bacteriophage of E. coli and host cells suitable for cloning are provided. The linear vectors include a left arm comprising a left telomere and a first selectable marker, a right arm comprising a right telomere and a second selectable marker and a cloning region located between the left arm and the right arm. Optional further components of the vector include transcriptional termination sequences, multiple cloning sites and reporter stuffer regions.
Type:
Grant
Filed:
January 12, 2007
Date of Patent:
May 12, 2015
Assignee:
Lucigen Corporation
Inventors:
Ronald Godiska, David A. Mead, Nikolai V. Ravin
Abstract: The present invention provides: genetically modified yeasts such as mutant yeasts having an ability to produce N-linked sugar chains of Man5GlcNAc2 and a decreased ability to produce O-linked sugar chains, mutant yeasts having an ability to produce N-linked sugar chains of Man5GlcNAc2 and further having an ability to produce N-linked sugar chains of GlcNAc1Man5GlcNAc2, and mutant yeasts having an increased ability to produce and secrete proteins and an ability to produce N-linked sugar chains of Man5GlcNAc2; and a method for producing glycoproteins using them.
Type:
Grant
Filed:
March 1, 2012
Date of Patent:
April 28, 2015
Assignee:
National Institute of Advanced Industrial Science and Technology
Abstract: Stalled ribosome:nascent molecule of interest complexes and methods of using same are provided. Plasmids, particularly DNA plasmids, comprising a stall segment are also disclosed. The methods provide for the facile and stable formation of stalled ribosome:nascent molecule of interest complexes that may be used to examine protein synthesis and protein conformational events, as well as in the creation of desired ribosomal displays. Cells transformed with these plasmids are also provided, and include both eukaryotic and prokaryotic transformed cells. Stall elements that provide for ribosomal stalling of eukaryotic and prokaryotic ribosomes are also disclosed. Various therapeutic and clinical applications of these methods are also provided and used in diseases associated with defects in protein accumulation in vivo.
Type:
Grant
Filed:
August 26, 2005
Date of Patent:
April 14, 2015
Inventors:
Patricia L. Clark, Michael S. Evans, Krastyu G. Ugrinov, Thomas Clarke, IV, Marc-André Frese
Abstract: The present invention provides a mutant 27 kDa NIa proteinase having reduced self-cleavage activity relative to the self-cleavage activity of its wild-type proteinase. The mutant has the same substrate cleavage activity as the wild-type proteinase but is more stable than the wild-type proteinase. The present invention also provides a method of obtaining large quantities of active 27 kDa NIa proteinase for use as a tool for purification of other proteins.
Type:
Grant
Filed:
May 21, 2013
Date of Patent:
March 3, 2015
Assignee:
Yale University
Inventors:
Jennifer A. Doudna, Louise J. Lucast, Robert T. Batey
Abstract: Methods for the cell-free identification of polypeptide and polypeptide combinations with utility in biomass transformation, as well as specific novel polypeptides and cell-free systems containing polypeptide combinations discovered by such methods are disclosed.
Abstract: Provided are methods and compositions for detecting the presence or amount of one or more target nucleic acids in a sample. Methods of the present invention include linking universal nucleic acid segments into a single molecule in a linking reaction dependent on a target nucleic acid of interest. A variety of universal segment linking strategies are provided, including preamplification by polymerase chain reaction, ligation-based strategies, reverse transcription and linear polymerase extension. Linking the universal segments into a single molecule generates a tagged target nucleic acid which is detected in a manner dependent on an intramolecular interaction between one universal segment and a second portion of the tagged target nucleic acid. In certain embodiments, the intramolecular interaction includes the formation of a hairpin having a stem between a universal segment at one end of the tagged target nucleic acid and a second universal segment at the opposite end of the tagged target nucleic acid.
Abstract: A method of transforming red microalgae is provided. The method is effected by: (i) culturing red microalgae cells under predetermined light/dilution conditions to thereby generate competent red microalgae cells; and (ii) introducing at least one exogenous polynucleotide into said competent red microalgae cells, thereby transforming the red microalgae.
Type:
Grant
Filed:
August 4, 2005
Date of Patent:
January 20, 2015
Assignees:
Ben-Gurion University of the Negev Research and Development Authority, Mor Research Applications Ltd.
Inventors:
Shoshana Arad, Miri Lapidot, Yacob Weinstein, Ron Dagan
Abstract: Disclosed herein are methods and compositions for targeted integration of one or more copies of a sequence of interest using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain and integrase defective lentiviral donor constructs.
Type:
Grant
Filed:
October 23, 2008
Date of Patent:
January 20, 2015
Assignees:
Sangamo BioSciences, Inc., Ospedale San Raffaele S.R.L.
Inventors:
Michael C. Holmes, Shuyuan Yao, Luigi Naldini, Angelo Leone Lombardo